Trial · NCT01491633
Dasatinib in Advanced Squamous Cell Lung Cancer
NCT01491633, Phase 2, Terminated, Dana-Farber Cancer Institute; results first posted 2014-07-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib in Advanced Squamous Cell Lung Cancer. Trials, record NCT01491633. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01491633
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib in Advanced Squamous Cell Lung Cancer
- NCT number
- NCT01491633
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Squamous Cell Lung Cancer
- Interventions
- Dasatinib
- First posted
- 2011-12-14
- Last updated
- 2014-07-15
- Results first posted
- 2014-07-15
- Limitations and caveats
- Due to the toxicity of the study agent no subjects were evaluable for response
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rate | 2 years | Determine the overall response rate of patients with squamous cell carcinoma of the lung treated with dasatinib |
| Secondary | Types and Frequency of DDR2 Mutations | 2 years | Determine frequency of DDR2 mutations in study patients |
| Secondary | Survival | 2 years | Establish the overall survival of patients with SCC treated with dasatinib |
| Secondary | Toxicities | 2 years | Define the toxicities of dasatinib when administered to the patient population. NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 will be utilized for adverse event reporting. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rate | 2 years | percent | NUMBER | |
| SECONDARY | Types and Frequency of DDR2 Mutations | 2 years | participants | NUMBER | |
| SECONDARY | Survival | 2 years | One subject who was alive at the end of the study was censored from the survival analysis | days | MEAN |
| SECONDARY | Toxicities | 2 years | grade 3 toxicities | NUMBER | |
| POST_HOC | Time on Study | 2 years | days | MEAN |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate | Dasatinib | NA | percent | ||
| Types and Frequency of DDR2 Mutations | Dasatinib | 0 | participants | ||
| Survival | Dasatinib | 112 | Standard Deviation 85 | days | |
| Toxicities | Dasatinib | 3 | grade 3 toxicities | ||
| Time on Study | Dasatinib | 22 | Standard Deviation 12 | days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dasatinib | 5 | |
| Overall Study | COMPLETED | Dasatinib | 0 | |
| Overall Study | NOT COMPLETED | Dasatinib | 5 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Dasatinib | 2 | 5 | 2 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib | 1 | 5 | 1 |
| other | Fatigue | General disorders | Dasatinib | 1 | 5 | 1 |
| other | Elevated LFTs | Gastrointestinal disorders | Dasatinib | 1 | 5 | 1 |
| other | Anorexia | General disorders | Dasatinib | 1 | 5 | 1 |
| other | Nausea | Gastrointestinal disorders | Dasatinib | 1 | 5 | 1 |
| serious | Hemoptysis | Respiratory, thoracic and mediastinal disorders | Dasatinib | 1 | 5 | 1 |
| serious | Death | General disorders | Dasatinib | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib | ||
| Total, other adverse events | Dasatinib | 5 | 5 |
| Total, serious adverse events | Dasatinib | 2 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24128713 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01491633
GET https://conductscience.org/api/trials/v1/NCT01491633/registered